Literature DB >> 30536202

Polyneuropathy in Severely Obese Women Without Diabetes: Prevalence and Associated Factors.

Lisiane Stefani Dias1, Otto Henrique Nienov1, Fernanda Dapper Machado1, Camila Perlin Ramos1, Daiane Rodrigues1, Rodrigo Koprovsky Menguer2, Helena Schmid3,4,5.   

Abstract

BACKGROUND: Obesity and its complications are prevalent in women and increase with age. Polyneuropathy (PNP) is a complication of obesity and bariatric surgery (BS). In subjects with severe (grades II and III) obesity and without DM who are candidates for BS, the prevalence of PNP and associated conditions are not well characterized. The aim of this study was to evaluate the prevalence of PNP in severely obese (SO) women without DM or common nutritional deficiencies in order to determine factors associated with the presence of PNP.
METHODS: A cross-sectional study was performed on 450 SO women. They were evaluated with the Michigan Neuropathy Screening Instrument, a Sleep Apnea Questionnaire, and the short form of the International Physical Activity Questionnaire. Data on blood pressure, body mass index, waist circumference, serum glucose, glycated hemoglobin, LDL and HDL cholesterol, triglycerides, vitamin B12, and postmenopausal (PM) status were also collected. Patients with DM and other common causes of PNP were excluded. To evaluate which variables were independently associated with PNP (dependent variable), Poisson regression models were used.
RESULTS: The prevalence of PNP was 11.6%. In univariate analysis, PNP was associated with age, PM status, and diagnosis of systemic arterial hypertension (p < 0.001, p < 0.001, and p = 0.016, respectively), and there was a trend toward an association with sleep apnea risk (p = 0.101). In multivariate analysis, PM status (PR = 2.836, 95% CI 1.735-4.636, p = 0.001) and age (PR = 1.0511, 95% CI 1.031-1.071, p = 0.001) were independently associated with PNP diagnosis in two different models.
CONCLUSION: Even prior to BS, PNP is highly prevalent and is associated with PM status and age in SO women without diabetes.

Entities:  

Keywords:  Aging; Bariatric surgery; Polyneuropathy; Postmenopause; Severe obesity

Mesh:

Year:  2019        PMID: 30536202     DOI: 10.1007/s11695-018-03627-0

Source DB:  PubMed          Journal:  Obes Surg        ISSN: 0960-8923            Impact factor:   4.129


  23 in total

Review 1.  Impaired glucose tolerance--does it cause neuropathy?

Authors:  J W Russell; E L Feldman
Journal:  Muscle Nerve       Date:  2001-09       Impact factor: 3.217

2.  Treatment for obstructive sleep apnoea: effect on peripheral nerve function.

Authors:  Rainer Dziewas; Matthias Schilling; Philipp Engel; Matthias Boentert; Hyon Hor; Angelika Okegwo; Peter Lüdemann; E Bernd Ringelstein; Peter Young
Journal:  J Neurol Neurosurg Psychiatry       Date:  2006-09-29       Impact factor: 10.154

Review 3.  Mechanisms of neuroprotection by estrogen.

Authors:  Shotaro Suzuki; Candice M Brown; Phyllis M Wise
Journal:  Endocrine       Date:  2006-04       Impact factor: 3.633

4.  Cross-cultural adaptation to Brazilian Portuguese of the Michigan Neuropathy Screening Instrument: MNSI-Brazil.

Authors:  Franassis Barbosa de Oliveira; Kárenn Klycia Pereira Botelho; Arthur Rodrigues Bezerra; Diego Igor de Oliveira Azevedo; Clarissa Cardoso Dos Santos-Couto-Paz; Emerson Fachin-Martins
Journal:  Arq Neuropsiquiatr       Date:  2016-08       Impact factor: 1.420

5.  Evaluation of Metabolic Syndrome in morbidly Obese Patients Submitted to Laparoscopic Bariatric Surgery: Comparison of the Results between Roux-En-Y Gastric Bypass and Sleeve Gastrectomy.

Authors:  Rodrigo Koprovski Menguer; Antônio Carlos Weston; Helena Schmid
Journal:  Obes Surg       Date:  2017-07       Impact factor: 4.129

6.  Risk factors for distal symmetric neuropathy in NIDDM. The San Luis Valley Diabetes Study.

Authors:  G M Franklin; S M Shetterly; J A Cohen; J Baxter; R F Hamman
Journal:  Diabetes Care       Date:  1994-10       Impact factor: 19.112

7.  Obesity and hyperlipidemia are risk factors for early diabetic neuropathy.

Authors:  A Gordon Smith; J Robinson Singleton
Journal:  J Diabetes Complications       Date:  2013-06-02       Impact factor: 2.852

8.  Peripheral polyneuropathy in severely obese patients with metabolic syndrome but without diabetes: Association with low HDL-cholesterol.

Authors:  Otto Henrique Nienov; Luciana Matte; Lisiane Stefani Dias; Helena Schmid
Journal:  Rev Assoc Med Bras (1992)       Date:  2017-04       Impact factor: 1.209

9.  Association Between Metabolic Syndrome Components and Polyneuropathy in an Obese Population.

Authors:  Brian C Callaghan; Rong Xia; Evan Reynolds; Mousumi Banerjee; Amy E Rothberg; Charles F Burant; Emily Villegas-Umana; Rodica Pop-Busui; Eva L Feldman
Journal:  JAMA Neurol       Date:  2016-12-01       Impact factor: 18.302

10.  Peripheral vascular disease and peripheral neuropathy in individuals with cardiometabolic clustering and obesity: National Health and Nutrition Examination Survey 2001-2004.

Authors:  Kelly R Ylitalo; MaryFran Sowers; Steven Heeringa
Journal:  Diabetes Care       Date:  2011-05-18       Impact factor: 19.112

View more
  2 in total

1.  Bariatric surgery leads to an improvement in small nerve fibre damage in subjects with obesity.

Authors:  Shazli Azmi; Maryam Ferdousi; Yifen Liu; Safwaan Adam; Zohaib Iqbal; Shaishav Dhage; Georgios Ponirakis; Tarza Siahmansur; Andrew Marshall; Ioannis Petropoulos; Alise Kalteniece; Jan Hoong Ho; Akheel Syed; John M Gibson; Basil J Ammori; Paul N Durrington; Rayaz A Malik; Handrean Soran
Journal:  Int J Obes (Lond)       Date:  2021-01-27       Impact factor: 5.095

2.  The role of abnormalities of lipoproteins and HDL functionality in small fibre dysfunction in people with severe obesity.

Authors:  Shazli Azmi; Maryam Ferdousi; Yifen Liu; Safwaan Adam; Tarza Siahmansur; Georgios Ponirakis; Andrew Marshall; Ioannis N Petropoulos; Jan Hoong Ho; Akheel A Syed; John M Gibson; Basil J Ammori; Paul N Durrington; Rayaz A Malik; Handrean Soran
Journal:  Sci Rep       Date:  2021-06-15       Impact factor: 4.379

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.